Curom announced that a research team led by Dr. Chil-yong Kang has applied for a hepatitis C patent around the world.
They further stated that this patent is regarding an innovative and unique technology regarding a hepatitis C virus vaccine. Sumagen Co., Ltd. has funded Dr. Kang’s research at Western Ontario University since 2006.
The research team has conducted tests on mice and was able to prove that their hepatitis C vaccine has excellent effects and that the side effects of VSV have been overcome.
Sumagen was able to add their hepatitis C vaccine to their new product pipeline in addition to the successfully-developing AIDS vaccine that is being carried out in North America.
There has been no treatment for complete cure of hepatitis C and the existent treatment methods have a high side effects-to-positive effects ratio, with a high cost and difficult method of consumption.
If Dr. Kang’s hepatitis C vaccine succeeds, then it will be the world’s first hepatitis C vaccine. It will not only serve as great news to many patients but will also bring about enormous economic effects.
DOWON INTERNATIONAL
5F. Shinwon Bldg. 823-14, Yeoksam-dong, Kangnam-ku, SEOUL, 135-080
KOREA
PHONE : 82-2-501-3106 FAX : 82-2-501-3109 e-mail : patyellow@dowon.com
Patent News
